Evidence map›Paper›PMID 40944700›Full record

ArticleEpilepsia open2025

Prospective evaluation of clinical characteristics, treatment efficacy, and seizure remission in adult-onset genetic generalized epilepsy.

Lourdes Khalife, Aya Harb, Fatima Jaafar, Ayman Beydoun, Jaafar Wazne, Hassan Toufaili, Badiee Moussa, Ahmad Beydoun

Abstract readMulticenter Study
In one paragraph

Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lourdes KhalifeDepartment of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.ORCID https://orcid.org/0009-0007-9634-9491
Aya HarbDepartment of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.ORCID https://orcid.org/0009-0003-1686-660X
Fatima JaafarDepartment of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.ORCID https://orcid.org/0000-0002-5519-9278
Ayman BeydounDepartment of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.ORCID https://orcid.org/0009-0008-5553-5332
Jaafar WazneRafic Hariri University Hospital, Beirut, Lebanon.ORCID https://orcid.org/0000-0003-2847-2619
Hassan ToufailiLabib Medical Center, Sidon, Lebanon.ORCID https://orcid.org/0000-0001-6382-5817
Badiee MoussaDepartment of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.ORCID https://orcid.org/0009-0003-5214-3839
Ahmad BeydounDepartment of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.ORCID https://orcid.org/0000-0002-9047-1185

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis prospective study aims to characterize the spectrum of epilepsy syndromes among adult patients newly diagnosed with genetic generalized epilepsy (GGE). Additionally, it aims to examine their clinical characteristics, evaluate their response to treatment, and assess the feasibility of treatment discontinuation across each syndrome.

methodsPatients identified for this study were recruited from a prospective multicenter study evaluating patients with new-onset unprovoked seizures enrolled between March 2010 and March 2020. Participants underwent a comprehensive evaluation including a 3-h sleep-deprived video-EEG recording and an epilepsy protocol brain MRI with repeat EEG at each follow-up. Included were patients 18 years and older and meeting criteria for GGE. Treatment responses, antiseizure medication (ASM) withdrawal success rates, and achievement of a two-year terminal seizure remission were assessed.

resultsA total of 67 patients with a mean age at seizure onset of 21.9 years were included, constituting 16% of the entire GGE cohort. The most frequently diagnosed electroclinical syndrome was GTCA in 34 patients (50.7%), followed by JME in 21 patients (31.3%) and GGE not otherwise specified (GGE-NOS) in 12 patients (17.9%). Most patients responded well to monotherapy with valproate and levetiracetam as the most frequently prescribed ASMs. ASM tapering was attempted in 28 patients and was more frequently successful in patients with GTCA and GGE-NOS (60%) compared with JME (12.5%). A two-year terminal seizure freedom for all seizure types was achieved in 85.3% of patients with GTCA, 83.3% of those with GGE-NOS, and 23.8% of those with JME. SIGNIFICANCE: This study provides comprehensive insights into the epidemiology, clinical features, and treatment outcomes of adult-onset GGE. It emphasizes the necessity of considering GGE in adults with new-onset seizures, highlighting the efficacy of ASM therapies and suggesting that certain electroclinical syndromes may not mandate lifelong treatment, underscoring the pivotal role of accurate diagnosis. PLAIN LANGUAGE SUMMARY: This study evaluated adults experiencing their first seizures who were diagnosed with a type of epilepsy called genetic generalized epilepsy (GGE). We found that this condition can begin in adulthood, and many patients have a family history of seizures. Most responded well to treatment, frequently with just one medication, and only a few continued to have seizures. In some, particularly those with generalized tonic-clonic seizures (whole-body convulsions), treatment could be safely stopped after several seizure-free years. These findings highlight the importance of accurate diagnosis and provide reassurance that good seizure control is achievable for most adults with GGE.

Indexed as

AnticonvulsantsEpilepsy, GeneralizedSeizuresAdolescentAdultElectroencephalographyFemaleHumansMaleMiddle AgedProspective StudiesRemission InductionTreatment OutcomeYoung AdultAnticonvulsantsadult onsetantiseizure medicationgenetic generalized epilepsyseizure outcometerminal remission

Identifiers

PMID40944700
PMCPMC12514359

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.